MIL •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeMIL
Market Capitalization957.9 mln
Float10.72 mln
Earnings Date09/23/2025
EPS
5.70
Strong
P / E
4.09
Deeply undervalued
Piotroski F-Score
8
/ 9
Very strong
Beneish M-Score
-0.91
Highly suspicious
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.03
Debt-free
Business Description
Founded in 1996 and headquartered in Siena, Italy, Philogen is a biotechnology company focused on developing targeted treatments for cancer and chronic inflammatory conditions, with operations across Switzerland and the European Union. The company has built a broad pipeline of antibody-based therapies and small molecule drug candidates, several of which are currently being evaluated in late-stage clinical trials for conditions such as melanoma, soft tissue sarcoma, and lung cancer. Philogen is also advancing earlier-stage programs aimed at diagnosing and treating a range of solid tumors, including prostate cancer and kidney cancer, using highly precise molecular targeting technology.
